Mitochondria-targeted cardioprotection in aldosteronism

Atta U Shahbaz1, German Kamalov, Wenyuan Zhao

  • 1Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Insights

Chronic aldosterone/salt treatment causes heart scarring by damaging mitochondria. Protecting mitochondria with quercetin or cyclosporine A prevents this damage, preserving heart structure and function.

Area of Science:

  • Cardiovascular Biology
  • Mitochondrial Medicine
  • Pharmacology

Background:

  • Chronic aldosterone/salt treatment (ALDOST) induces myocardial structural remodeling and cardiomyocyte necrosis, leading to scarring.
  • Previous research suggests intramitochondrial calcium overload, oxidative stress, and mitochondrial permeability transition pore (mPTP) opening are key pathways in ALDOST-induced cell death.

Purpose of the Study:

  • To validate the cardioprotective potential of mitochondria-targeted interventions against ALDOST-induced myocardial damage.
  • To investigate the role of mitochondria in mediating necrotic cell death and fibrosis during ALDOST.

Main Methods:

  • Male Sprague-Dawley rats received ALDOST for 4 weeks, with co-treatment of quercetin (antioxidant) or cyclosporine A (mPTP inhibitor).
  • Measurements included mitochondrial calcium, oxidative stress biomarkers (8-isoprostane, H2O2), mPTP opening, total tissue calcium, and collagen volume fraction (fibrosis).
  • Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was used to assess apoptosis.

Main Results:

  • ALDOST significantly increased mitochondrial oxidative stress, mPTP opening, and calcium levels, leading to a 5-fold increase in myocardial fibrosis.
  • No evidence of cardiomyocyte apoptosis was detected via TUNEL assay.
  • Quercetin and cyclosporine A co-treatments effectively prevented all observed ALDOST-induced pathophysiological changes.

Conclusions:

  • Mitochondria are central to the mechanisms driving necrotic cell death and myocardial scarring in response to ALDOST.
  • Mitochondria-targeted interventions, such as quercetin and cyclosporine A, demonstrate significant cardioprotective effects, preserving cardiac structure.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...